Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 11/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13690889 | 1.00 | KMT2A (0.41) | KMT2AMEN1TSHRHSD17B10ALDH1A1 | |
| SCHEMBL4049704 | 0.85 | ALDH1A1 (0.40) | ALDH1A1RAB9AKDM4ERECQL | |
| SCHEMBL13689033 | 0.83 | KMT2A (0.44) | KMT2AMEN1TSHRHSD17B10ALDH1A1 | |
| SCHEMBL12884853 | 0.83 | KMT2A (0.44) | KMT2AMEN1TSHRHSD17B10ALDH1A1 | |
| SCHEMBL12898783 | 0.76 | ALDH1A1 (0.42) | TSHRALDH1A1LMNARAB9AKDM4E | |
| SCHEMBL13688986 | 0.76 | ALDH1A1 (0.42) | TSHRALDH1A1LMNARAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL1215813 | 0.75 | ALDH1A1 (0.41) | TSHRALDH1A1LMNARAB9AKDM4E | |
| SCHEMBL1217329 | 0.75 | KMT2A (0.48) | KMT2ATSHRHSD17B10ALDH1A1LMNA | |
| SCHEMBL13689032 | 0.73 | CTSK (0.49) | KMT2ATSHRHSD17B10ALDH1A1LMNA | |
| SCHEMBL1218083 | 0.73 | CTSK (0.49) | KMT2ATSHRHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | KMT2A 3459/4885MEN1 1806/4885TSHR 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.